LOCUS NP_001124176 820 aa linear PRI 01-JUN-2024
DEFINITION disintegrin and metalloproteinase domain-containing protein 29
preproprotein [Homo sapiens].
ACCESSION NP_001124176
VERSION NP_001124176.1
DBSOURCE REFSEQ: accession NM_001130704.1
KEYWORDS RefSeq.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
Catarrhini; Hominidae; Homo.
REFERENCE 1 (residues 1 to 820)
AUTHORS Zhao,M., Jia,W., Jiang,W.G., Wang,P., DU,G., Cheng,S. and Song,M.
TITLE ADAM29 Expression in Human Breast Cancer and its Effects on Breast
Cancer Cells In Vitro
JOURNAL Anticancer Res 36 (3), 1251-1258 (2016)
PUBMED 26977022
REMARK GeneRIF: Increased transcript expression of ADAM29 was observed in
breast cancer tissues compared to normal ones. The expression of
ADAM29 and its mutations in different domains significantly
influenced proliferation, migration and invasion of breast cancer
cells in vitro.
REFERENCE 2 (residues 1 to 820)
AUTHORS Lin,S.W., Tsai,C.N., Lee,Y.S., Chu,S.F. and Chen,N.H.
TITLE Gene expression profiles in peripheral blood mononuclear cells of
Asian obstructive sleep apnea patients
JOURNAL Biomed J 37 (2), 60-70 (2014)
PUBMED 24732660
REMARK GeneRIF: PCMC expression of ADAM29, FLRT2, and SLC18A3 could be
assessed as part of a routine screen to help identify individuals
at risk of severe Obstructive sleep apnea in Asian populations
REFERENCE 3 (residues 1 to 820)
AUTHORS Michailidou,K., Hall,P., Gonzalez-Neira,A., Ghoussaini,M.,
Dennis,J., Milne,R.L., Schmidt,M.K., Chang-Claude,J., Bojesen,S.E.,
Bolla,M.K., Wang,Q., Dicks,E., Lee,A., Turnbull,C., Rahman,N.,
Fletcher,O., Peto,J., Gibson,L., Dos Santos Silva,I.,
Nevanlinna,H., Muranen,T.A., Aittomaki,K., Blomqvist,C., Czene,K.,
Irwanto,A., Liu,J., Waisfisz,Q., Meijers-Heijboer,H., Adank,M., van
der Luijt,R.B., Hein,R., Dahmen,N., Beckman,L., Meindl,A.,
Schmutzler,R.K., Muller-Myhsok,B., Lichtner,P., Hopper,J.L.,
Southey,M.C., Makalic,E., Schmidt,D.F., Uitterlinden,A.G.,
Hofman,A., Hunter,D.J., Chanock,S.J., Vincent,D., Bacot,F.,
Tessier,D.C., Canisius,S., Wessels,L.F., Haiman,C.A., Shah,M.,
Luben,R., Brown,J., Luccarini,C., Schoof,N., Humphreys,K., Li,J.,
Nordestgaard,B.G., Nielsen,S.F., Flyger,H., Couch,F.J., Wang,X.,
Vachon,C., Stevens,K.N., Lambrechts,D., Moisse,M., Paridaens,R.,
Christiaens,M.R., Rudolph,A., Nickels,S., Flesch-Janys,D.,
Johnson,N., Aitken,Z., Aaltonen,K., Heikkinen,T., Broeks,A.,
Veer,L.J., van der Schoot,C.E., Guenel,P., Truong,T.,
Laurent-Puig,P., Menegaux,F., Marme,F., Schneeweiss,A., Sohn,C.,
Burwinkel,B., Zamora,M.P., Perez,J.I., Pita,G., Alonso,M.R.,
Cox,A., Brock,I.W., Cross,S.S., Reed,M.W., Sawyer,E.J.,
Tomlinson,I., Kerin,M.J., Miller,N., Henderson,B.E., Schumacher,F.,
Le Marchand,L., Andrulis,I.L., Knight,J.A., Glendon,G.,
Mulligan,A.M., Lindblom,A., Margolin,S., Hooning,M.J.,
Hollestelle,A., van den Ouweland,A.M., Jager,A., Bui,Q.M.,
Stone,J., Dite,G.S., Apicella,C., Tsimiklis,H., Giles,G.G.,
Severi,G., Baglietto,L., Fasching,P.A., Haeberle,L., Ekici,A.B.,
Beckmann,M.W., Brenner,H., Muller,H., Arndt,V., Stegmaier,C.,
Swerdlow,A., Ashworth,A., Orr,N., Jones,M., Figueroa,J.,
Lissowska,J., Brinton,L., Goldberg,M.S., Labreche,F., Dumont,M.,
Winqvist,R., Pylkas,K., Jukkola-Vuorinen,A., Grip,M., Brauch,H.,
Hamann,U., Bruning,T., Radice,P., Peterlongo,P., Manoukian,S.,
Bonanni,B., Devilee,P., Tollenaar,R.A., Seynaeve,C., van
Asperen,C.J., Jakubowska,A., Lubinski,J., Jaworska,K., Durda,K.,
Mannermaa,A., Kataja,V., Kosma,V.M., Hartikainen,J.M.,
Bogdanova,N.V., Antonenkova,N.N., Dork,T., Kristensen,V.N.,
Anton-Culver,H., Slager,S., Toland,A.E., Edge,S., Fostira,F.,
Kang,D., Yoo,K.Y., Noh,D.Y., Matsuo,K., Ito,H., Iwata,H., Sueta,A.,
Wu,A.H., Tseng,C.C., Van Den Berg,D., Stram,D.O., Shu,X.O., Lu,W.,
Gao,Y.T., Cai,H., Teo,S.H., Yip,C.H., Phuah,S.Y., Cornes,B.K.,
Hartman,M., Miao,H., Lim,W.Y., Sng,J.H., Muir,K., Lophatananon,A.,
Stewart-Brown,S., Siriwanarangsan,P., Shen,C.Y., Hsiung,C.N.,
Wu,P.E., Ding,S.L., Sangrajrang,S., Gaborieau,V., Brennan,P.,
McKay,J., Blot,W.J., Signorello,L.B., Cai,Q., Zheng,W.,
Deming-Halverson,S., Shrubsole,M., Long,J., Simard,J.,
Garcia-Closas,M., Pharoah,P.D., Chenevix-Trench,G., Dunning,A.M.,
Benitez,J. and Easton,D.F.
CONSRTM Breast and Ovarian Cancer Susceptibility Collaboration; Hereditary
Breast and Ovarian Cancer Research Group Netherlands (HEBON);
kConFab Investigators; Australian Ovarian Cancer Study Group;
GENICA (Gene Environment Interaction and Breast Cancer in Germany)
Network
TITLE Large-scale genotyping identifies 41 new loci associated with
breast cancer risk
JOURNAL Nat Genet 45 (4), 353-361 (2013)
PUBMED 23535729
REFERENCE 4 (residues 1 to 820)
AUTHORS Wei,X., Moncada-Pazos,A., Cal,S., Soria-Valles,C., Gartner,J.,
Rudloff,U., Lin,J.C., Rosenberg,S.A., Lopez-Otin,C. and Samuels,Y.
CONSRTM NISC Comparative Sequencing Program
TITLE Analysis of the disintegrin-metalloproteinases family reveals
ADAM29 and ADAM7 are often mutated in melanoma
JOURNAL Hum Mutat 32 (6), E2148-E2175 (2011)
PUBMED 21618342
REMARK GeneRIF: mutated ADAM27 and ADAM7 genes could play a role in
melanoma progression.
REFERENCE 5 (residues 1 to 820)
AUTHORS Maloum,K., Settegrana,C., Chapiro,E., Cazin,B., Lepretre,S.,
Delmer,A., Leporrier,M., Dreyfus,B., Tournilhac,O., Mahe,B.,
Nguyen-Khac,F., Lesty,C., Davi,F. and Merle-Beral,H.
TITLE IGHV gene mutational status and LPL/ADAM29 gene expression as
clinical outcome predictors in CLL patients in remission following
treatment with oral fludarabine plus cyclophosphamide
JOURNAL Ann Hematol 88 (12), 1215-1221 (2009)
PUBMED 19340428
REMARK GeneRIF: Results support the use of LPL and ADAM29 gene expression
associated to IGHV mutational status for predicting the clinical
outcome of patients treated by oral fludarabine + cyclophosphamide
and could be considered for treatment strategies.
REFERENCE 6 (residues 1 to 820)
AUTHORS Oppezzo,P., Vasconcelos,Y., Settegrana,C., Jeannel,D., Vuillier,F.,
Legarff-Tavernier,M., Kimura,E.Y., Bechet,S., Dumas,G.,
Brissard,M., Merle-Beral,H., Yamamoto,M., Dighiero,G. and Davi,F.
CONSRTM French Cooperative Group on CLL
TITLE The LPL/ADAM29 expression ratio is a novel prognosis indicator in
chronic lymphocytic leukemia
JOURNAL Blood 106 (2), 650-657 (2005)
PUBMED 15802535
REMARK GeneRIF: quantification of LPL and ADAM29 gene expression is a
strong prognostic indicator in CLL, providing better prognostic
assessment than ZAP-70 in advanced stages of the disease
REFERENCE 7 (residues 1 to 820)
AUTHORS Xu,R., Cai,J., Xu,T., Zhou,W., Ying,B., Deng,K., Zhao,S. and Li,C.
TITLE Molecular cloning and mapping of a novel ADAM gene (ADAM29) to
human chromosome 4
JOURNAL Genomics 62 (3), 537-539 (1999)
PUBMED 10644455
REFERENCE 8 (residues 1 to 820)
AUTHORS Cerretti,D.P., DuBose,R.F., Black,R.A. and Nelson,N.
TITLE Isolation of two novel metalloproteinase-disintegrin (ADAM) cDNAs
that show testis-specific gene expression
JOURNAL Biochem Biophys Res Commun 263 (3), 810-815 (1999)
PUBMED 10512762
COMMENT REVIEWED REFSEQ: This record has been curated by NCBI staff. The
reference sequence was derived from DB073142.1, DB080702.1,
AK292410.1 and BC036070.1.
Summary: This gene encodes a member of the ADAM (a disintegrin and
metalloprotease domain) family. Members of this family are
membrane-anchored proteins structurally related to snake venom
disintegrins, and have been implicated in a variety of biological
processes involving cell-cell and cell-matrix interactions,
including fertilization, muscle development, and neurogenesis. The
protein encoded by this gene is highly expressed in testis and may
be involved in human spermatogenesis. Alternative splicing results
in multiple transcript variants that encode the same protein.
[provided by RefSeq, Jul 2008].
Transcript Variant: This variant (3) differs in the 5' UTR,
compared to variant 1. Variants 1, 2, 3, 4, 5, 6, and 7 encode the
same protein.
##Evidence-Data-START##
Transcript exon combination :: AK292410.1, BI561525.1 [ECO:0000332]
RNAseq introns :: single sample supports all introns
SAMEA1968968, SAMEA2148093
[ECO:0000348]
##Evidence-Data-END##
FEATURES Location/Qualifiers
source 1..820
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="4"
/map="4q34.1"
Protein 1..820
/product="disintegrin and metalloproteinase
domain-containing protein 29 preproprotein"
/note="a disintegrin and metalloproteinase domain 29;
cancer/testis antigen 73; disintegrin and
metalloproteinase domain-containing protein 29;
metallaproteinase-disintegrin (ADAM29); testis secretory
sperm-binding protein Li 207a; epididymis secretory sperm
binding protein"
/calculated_mol_wt=90812
sig_peptide 1..18
/inference="COORDINATES: ab initio prediction:SignalP:6.0"
/calculated_mol_wt=1966
proprotein 19..820
/product="disintegrin and metalloproteinase
domain-containing protein 29 proprotein"
/calculated_mol_wt=90812
Region 32..150
/region_name="Pep_M12B_propep"
/note="Reprolysin family propeptide; pfam01562"
/db_xref="CDD:460254"
mat_peptide 194..820
/product="Disintegrin and metalloproteinase
domain-containing protein 29. /id=PRO_0000029135"
/note="propagated from UniProtKB/Swiss-Prot (Q9UKF5.3)"
/calculated_mol_wt=70710
Region 198..386
/region_name="ZnMc_adamalysin_II_like"
/note="Zinc-dependent metalloprotease; adamalysin_II_like
subfamily. Adamalysin II is a snake venom zinc
endopeptidase. This subfamily contains other snake venom
metalloproteinases, as well as membrane-anchored
metalloproteases belonging to the ADAM family; cd04269"
/db_xref="CDD:239797"
Site 217
/site_type="glycosylation"
/note="N-linked (GlcNAc...) asparagine.
/evidence=ECO:0000255; propagated from
UniProtKB/Swiss-Prot (Q9UKF5.3)"
Site 320
/site_type="glycosylation"
/note="N-linked (GlcNAc...) asparagine.
/evidence=ECO:0000255; propagated from
UniProtKB/Swiss-Prot (Q9UKF5.3)"
Site order(332..333,336,342)
/site_type="active"
/db_xref="CDD:239797"
Site 368
/site_type="glycosylation"
/note="N-linked (GlcNAc...) asparagine.
/evidence=ECO:0000255; propagated from
UniProtKB/Swiss-Prot (Q9UKF5.3)"
Region 406..478
/region_name="Disintegrin"
/note="pfam00200"
/db_xref="CDD:459709"
Site 428
/site_type="glycosylation"
/note="N-linked (GlcNAc...) asparagine.
/evidence=ECO:0000255; propagated from
UniProtKB/Swiss-Prot (Q9UKF5.3)"
Site 469
/site_type="glycosylation"
/note="N-linked (GlcNAc...) asparagine.
/evidence=ECO:0000255; propagated from
UniProtKB/Swiss-Prot (Q9UKF5.3)"
Region 483..618
/region_name="ACR"
/note="ADAM Cysteine-Rich Domain; smart00608"
/db_xref="CDD:214743"
Site 538
/site_type="glycosylation"
/note="N-linked (GlcNAc...) asparagine.
/evidence=ECO:0000255; propagated from
UniProtKB/Swiss-Prot (Q9UKF5.3)"
Site 545
/site_type="glycosylation"
/note="N-linked (GlcNAc...) asparagine.
/evidence=ECO:0000255; propagated from
UniProtKB/Swiss-Prot (Q9UKF5.3)"
Site 558
/site_type="glycosylation"
/note="N-linked (GlcNAc...) asparagine.
/evidence=ECO:0000255; propagated from
UniProtKB/Swiss-Prot (Q9UKF5.3)"
Site 564
/site_type="glycosylation"
/note="N-linked (GlcNAc...) asparagine.
/evidence=ECO:0000255; propagated from
UniProtKB/Swiss-Prot (Q9UKF5.3)"
Site 675..695
/site_type="transmembrane region"
/note="propagated from UniProtKB/Swiss-Prot (Q9UKF5.3)"
Region <701..>819
/region_name="Atrophin-1"
/note="Atrophin-1 family; pfam03154"
/db_xref="CDD:460830"
Region 706..820
/region_name="Disordered.
/evidence=ECO:0000256|SAM:MobiDB-lite"
/note="propagated from UniProtKB/Swiss-Prot (Q9UKF5.3)"
Region 739..819
/region_name="9 X 9 AA approximate repeats"
/note="propagated from UniProtKB/Swiss-Prot (Q9UKF5.3)"
CDS 1..820
/gene="ADAM29"
/gene_synonym="CT73; svph1"
/coded_by="NM_001130704.1:565..3027"
/db_xref="CCDS:CCDS3823.1"
/db_xref="GeneID:11086"
/db_xref="HGNC:HGNC:207"
/db_xref="MIM:604778"
ORIGIN
1 mkmllllhcl gvflscsghi qdehpqyhsp pdvvipvrit gttrgmtppg wlsyilpfgg
61 qkhiihikvk kllfskhlpv ftytdqgail edqpfvqnnc yyhgyvegdp eslvslstcf
121 ggfqgilqin dfayeikpla fsttfehlvy kmdseekqfs tmrsgfmqne itcrmefeei
181 dnstqkqssy vgwwihfriv eivvvidnyl yiryerndsk lledlyvivn ivdsildvig
241 vkvllfglei wtnknlivvd dvrksvhlyc kwksenitpr mqhdtshlft tlglrglsgi
301 gafrgmctph rscaivtfmn ktlgtfsiav ahhlghnlgm nhdedtcrcs qprcimhegn
361 ppitkfsncs ygdfweytve rtkclletvh tkdifnvkrc gngvveegee cdcgplkhca
421 kdpcclsnct ltdgstcafg lcckdckflp sgkvcrkevn ecdlpewcng tshkcpddfy
481 vedgipcker gycyekschd rneqcrrifg agantasetc ykelntlgdr vghcgiknat
541 yikcnisdvq cgriqcenvt eipnmsdhtt vhwarfndim cwstdyhlgm kgpdigevkd
601 gtecgidhic ihrhcvhiti lnsncspafc nkrgicnnkh hchcnylwdp pnclikgygg
661 svdsgpppkr kkkkkfcylc illlivlfil lcclyrlckk skpikkqqdv qtpsakeeek
721 iqrrphelpp qsqpwvmpsq sqppvtpsqs hpqvmpsqsq ppvtpsqsqp rvmpsqsqpp
781 vmpsqshpql tpsqsqppvt psqrqpqlmp sqsqppvtps
//